TIZIN ALERDZHI SPRAY 50MKG/DOSE

Indications

- symptomatic therapy of seasonal and year-round allergic rhinitis.

Dosing regimen

Intranasally administered adults and children over 6 years 2 doses (100 mcg) in each nasal passage 2 times / day. Use of the drug should be continued until symptoms are eliminated. With more severe symptoms, the drug can be used 3-4 times / day.

The patient should be warned about the need to clear the nasal cavity before using the spray and inhale through the nose during the injection.

Before first use, remove the protective cap and repeatedly press the spray nozzle until a mist appears. The bottle is ready for further use. Drug inhale through the nose.

Shake the bottle before each use.

Side effect

Adverse events reported in ≥1% of patients during clinical trials

From the digestive system: nausea.

Nervous system: headache, drowsiness, dizziness.

Respiratory: sore throat and larynx, nosebleeds, cough.

Other: fatigue, pain at the injection site.

Adverse reactions that have been reported in <1% of patients during clinical trials

From the side of the respiratory system: short-term local irritation, pain at the injection site, dryness, burning sensation, discomfort in the nasal cavity.

Post-marketing data

Determination of the frequency of adverse reactions: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (> 1/10 000, <1 / 1000), very rarely (<1/10 000, including isolated cases).

Cardiovascular: rarely - tachycardia.

Immune system: infrequently - allergic reactions.

Respiratory: rarely - swelling of the nasal mucosa; infrequently - shortness of breath; frequency is unknown - bronchospasm.

Other: infrequently - indisposition; frequency is unknown - swelling of the eyelids.

Contraindications

- children's age up to 6 years;

- hypersensitivity to the drug.

WITH caution It should be prescribed to patients with impaired renal function and elderly patients.

Use during pregnancy and lactation

Reliable data on the use of nasal spray Tizin ® Alergi in pregnant women are absent.Therefore, the drug should not be used during pregnancy unless the intended benefit to the mother justifies the potential risk to the fetus.

Based on the determination of the concentration of levocabastin in the saliva and breast milk of lactating women who received 0.5 mg of levocabastin once inside, it is expected that approximately 0.6% of the total intranasal dose of levocabastin can be administered to the baby during breastfeeding. If necessary, the appointment of the drug during lactation should stop breastfeeding.

Application for violations of kidney function

WITH caution It should be prescribed to patients with impaired renal function.

Use in children

Do not use for children under 6 years old.

Use in elderly patients

WITH caution the drug should be prescribed to elderly patients.

special instructions

Influence on ability to drive motor transport and control mechanisms

The drug in the recommended dose usually does not have a clinically pronounced sedative effect and does not reduce the speed of the reaction compared with placebo. In the case of drowsiness in the use of the drug should not engage in potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Disposal rules

The patient should be informed that if the drug has become unusable or the expiration date has expired, then it should not be thrown into the wastewater or on the street. It is necessary to put the drug in the bag and put it in the trash. These measures will help protect the environment.

Overdose

No reports of overdose of levocabastine have been reported.

Symptoms: with accidental ingestion may decrease blood pressure, tachycardia, a small sedative effect.

Treatment: if ingested, the patient should drink a large amount of fluid to speed up the release of levocabastine by the kidneys.

Terms and conditions of storage

The drug should be stored out of the reach of children at a temperature not higher than 25 ° C.